SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies

被引：0

作者：

Hart, Stefan ^{[1
]}

Goh, Kee Chuan ^{[1
]}

Novotny-Diermayr, Veronica Veronica ^{[1
]}

Tan, Yong Cheng ^{[1
]}

Madan, Babita ^{[1
]}

Amalini, Chithra ^{[1
]}

Loh, Yung Kiang ^{[1
]}

Ong, Lai Chun ^{[1
]}

Williams, Anthony ^{[1
]}

Lee, Angeline ^{[1
]}

Poulsen, Anders ^{[1
]}

Jayaraman, Ramesh ^{[1
]}

Ethirajulu, Kantharaj ^{[1
]}

Dymock, Brian W. ^{[1
]}

Wood, Jeanette M. ^{[1
]}

机构：

[1] S BIO PTE LTD, Singapore, Singapore

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.AM2011-3570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3570

引用

页数：1

共 50 条

[41] PACRITINIB Inhibitor of Tyrosine-Protein Kinase JAK2 Inhibitor of FLT-3 Treatment of Myelofibrosis
Verstovsek, S.
Machida, C.
Dean, J. P.
Myint, H.
DRUGS OF THE FUTURE, 2013, 38 (06) : 375 - 386
[42] Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate
Zhu, Jiali
Yang, Tao
Tang, Minghai
Yang, Zhuang
Pei, Heying
Ye, Haoyu
Tang, Yu
Cheng, Zhixuan
Lin, Ping
Chen, Lijuan
BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
[43] Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes
Younes, Anas
Fanale, Michelle A.
McLaughlin, Peter
Copeland, Amanda
Zhu, Joy
Faria, Silvania de Castro
BLOOD, 2010, 116 (21) : 1167 - 1167
[44] A novel and potent FLT3 and IRAK4 dual inhibitor for the treatment of acute myeloid leukemia
Yang, Rui
Wu, Lei
Zhang, Bing
Xiang, Michael
Wang, Suyue
Xiang, Camille
Lu, Zhijian
Xiang, Jason
CANCER RESEARCH, 2023, 83 (07)
[45] Orally efficacious, selective FLT3 inhibitor for the treatment of acute myeloid leukemia
Kreutter, Kevin
Baindur, Nand
Xu, Guozhang
Kim, Alexander J.
Baumann, Christian A.
Tuman, Robert W.
Johnson, Dana L.
Gaul, Micheal D.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[46] Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
Azhar, Mohammad
Kincaid, Zachary
Kesarwani, Meenu
Menke, Jacob
Schwieterman, Joshua
Ansari, Sekhu
Reaves, Angela
Ahmed, Arhama
Shehzad, Rammsha
Khan, Areeba
Syed, Nuha
Amir, Noor
Wunderlich, Mark
Latif, Tahir
Seibel, William
Azam, Mohammad
BLOOD ADVANCES, 2023, 7 (08) : 1460 - 1476
[47] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon
Qiuhong Zhao
Daelynn R. Buelow
Mitch Phelps
Alison R. Walker
Alice S. Mims
Sumithira Vasu
Gregory Behbehani
James Blachly
William Blum
Rebecca B. Klisovic
John C. Byrd
Ramiro Garzon
Sharyn D. Baker
Bhavana Bhatnagar
Investigational New Drugs, 2020, 38 : 340 - 349
[48] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jeon, Jae Yoon
Zhao, Qiuhong
Buelow, Daelynn R.
Phelps, Mitch
Walker, Alison R.
Mims, Alice S.
Vasu, Sumithira
Behbehani, Gregory
Blachly, James
Blum, William
Klisovic, Rebecca B.
Byrd, John C.
Garzon, Ramiro
Baker, Sharyn D.
Bhatnagar, Bhavana
INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 340 - 349
[49] TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
Goh, K. C.
Novotny-Diermayr, V.
Hart, S.
Ong, L. C.
Loh, Y. K.
Cheong, A.
Tan, Y. C.
Hu, C.
Jayaraman, R.
William, A. D.
Sun, E. T.
Dymock, B. W.
Ong, K. H.
Ethirajulu, K.
Burrows, F.
Wood, J. M.
LEUKEMIA, 2012, 26 (02) : 236 - 243
[50] TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
K C Goh
V Novotny-Diermayr
S Hart
L C Ong
Y K Loh
A Cheong
Y C Tan
C Hu
R Jayaraman
A D William
E T Sun
B W Dymock
K H Ong
K Ethirajulu
F Burrows
J M Wood
Leukemia, 2012, 26 : 236 - 243

← 1 2 3 4 5 →